李子健 Zijian Li

北京大学第三医院教授，博士生导师，心血管受体研究北京市重点实验室主任，中国病理生理学会副秘书长，中国病理生理学会受体信号转导专业委员会副主任委员，中国病理生理学会血管医学专业委员会副主任委员，北京市药理学会心脑血管专业委员会副主任委员/秘书长等。Molecular Pharmacology，Cardiology Plus等国内外杂志编委。主持国家课题各级20余项，包括国家自然科学基金血管重大研究计划集成项目（首席科学家）、国自然重点国际合作项目、国自然重点区域合作项目、面上项目、国家”973″项目、”重大新药创制”科技重大专项目子课题等20余项课题。系列研究在Cell子刊Trends in cell biology, Trends in Pharmacological Sciences，Eur Heart J，cell research，Pharmacology and Therapeutics，Cell Death and Differentiation, Acta Pharmaceutica Sinica B等发表SCI论文100余篇。第一发明人获得国家发明专利授权9项。获省部级科技进步一等奖4项。

Professor at Peking University Third Hospital, doctoral supervisor, Director of Beijing Key Laboratory of Cardiovascular Receptor Research, Deputy Secretary-General of Chinese Association of Pathophysiology, Vice Chairman of the Professional Committee on Receptor Signal Transduction of Chinese Association of Pathophysiology, Vice Chairman of the Professional Committee on Vascular Medicine of Chinese Association of Pathophysiology, Vice Chairman/Secretary-General of the Professional Committee on Cardiovascular and Cerebrovascular of Beijing Society of Pharmacology. Serves as editorial board member for journals such as Molecular Pharmacology and Cardiology Plus. Has led over 20 national-level projects including NSFC Major Research Plan Integration Project on Vascular Research (Chief Scientist), NSFC Key International Cooperation Project, NSFC Key Regional Cooperation Project, General Projects, National “973” Project, and sub-projects of “Major New Drug Development” National Science and Technology Major Project. Series of studies have published over 100 SCI papers in Cell subsidiary journals Trends in Cell Biology, Trends in Pharmacological Sciences, Eur Heart J, Cell Research, Pharmacology and Therapeutics, Cell Death and Differentiation, Acta Pharmaceutica Sinica B, etc. As first inventor, has been granted 9 national invention patents. Has received 4 first prizes for provincial and ministerial-level scientific and technological progress.

研究方向：心血管临床药学/心血管药理学

Research Direction: Cardiovascular Clinical Pharmacy/Cardiovascular Pharmacology

1. Kaihang Guan, Zijian Li*. β-adrenergic receptor inhibits heart regeneration by downregulating Yap m6A modification. Cell Death Dis. 2025,14;16(1):294.
2. Xuening Liu, Zijian Li*. The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity. Basic Res Cardiol. 2025;120(1):11-24.